Ross\Johnson & Associates’s Transmedics TMDX Stock Holding History

Ross\Johnson & Associates’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$243	–	333
2025 Q4	$243	Buy	+2	New	+$251	﹤0.01%	230

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ross\Johnson & Associates's TMDX Position: Q1 2026 in Review

Ross\Johnson & Associates sold out of Transmedics (TMDX) in Q1 2026, closing a stake of 2 shares — an estimated $243 sold.

Ross\Johnson & Associates first reported a position in TMDX in Q4 2025 and held it in 1 quarter. The position peaked at $243 in Q4 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Ross\Johnson & Associates reported no remaining Transmedics position as of Q1 2026 after selling out during the quarter.
Ross\Johnson & Associates sold 2 Transmedics shares in Q1 2026, an estimated $243.
Ross\Johnson & Associates first reported a position in Transmedics in Q4 2025 and held it in 1 quarter.
Ross\Johnson & Associates's Transmedics position peaked at $243 in Q4 2025.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.